Weekly Recap: $920M July 2026 raise and ABTECT Phase 3 obefazimod success

Abivax SA Sponsored ADR (EURONEXT:ABVX) bolstered its balance sheet with a July 2026 offering raising about $920M (net ~$874M), leaving €402.4M cash and runway into Q4 2029, after positive June 29 Phase 3 ABTECT maintenance results for obefazimod in refractory ulcerative colitis.Previous Week Recap…